60+ health care groups urge CMS to maintain coverage for medically necessary cancer testing

(Association for Molecular Pathology) Leading health care companies and organizations representing patients, providers, academic medical centers, laboratories, and diagnostic manufacturers urged the Centers for Medicare and Medicaid Services (CMS) to revise its interpretation of the National Coverage Determination (NCD) for Next Generation Sequencing. In a letter to CMS Administrator Seema Verma, 63 organizations expressed serious concerns that the overly broad interpretation will restrict patient access to medically necessary and relevant clinical tests and adversely impact cancer care and outcomes.

Source: EurekAlert! - Medicine and Health - February 1, 2019 Category: International Medicine & Public Health Source Type: news